935 Shares in Intuitive Surgical, Inc. (NASDAQ:ISRG) Bought by University of Texas Texas AM Investment Management Co.

University of Texas Texas AM Investment Management Co. purchased a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the second quarter, according to its most recent filing with the SEC. The firm purchased 935 shares of the medical equipment provider’s stock, valued at approximately $416,000.

Several other hedge funds have also recently made changes to their positions in the business. One Wealth Management Investment & Advisory Services LLC raised its holdings in Intuitive Surgical by 3.4% in the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock worth $310,000 after purchasing an additional 23 shares in the last quarter. Indiana Trust & Investment Management CO raised its holdings in shares of Intuitive Surgical by 5.3% during the second quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after purchasing an additional 25 shares during the last quarter. Hoxton Planning & Management LLC lifted its holdings in shares of Intuitive Surgical by 4.9% during the 2nd quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock valued at $238,000 after buying an additional 25 shares during the period. First Affirmative Financial Network grew its holdings in shares of Intuitive Surgical by 2.7% in the second quarter. First Affirmative Financial Network now owns 996 shares of the medical equipment provider’s stock worth $443,000 after acquiring an additional 26 shares during the period. Finally, Moors & Cabot Inc. increased its position in Intuitive Surgical by 2.3% during the second quarter. Moors & Cabot Inc. now owns 1,159 shares of the medical equipment provider’s stock valued at $516,000 after acquiring an additional 26 shares during the last quarter. 83.64% of the stock is owned by institutional investors.

Insider Activity at Intuitive Surgical

In related news, EVP Myriam Curet sold 2,818 shares of Intuitive Surgical stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $1,291,010.34. Following the sale, the executive vice president now directly owns 298 shares in the company, valued at approximately $136,522.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Amy L. Ladd sold 450 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $490.28, for a total value of $220,626.00. Following the transaction, the director now owns 821 shares of the company’s stock, valued at $402,519.88. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Myriam Curet sold 2,818 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $1,291,010.34. Following the transaction, the executive vice president now owns 298 shares in the company, valued at $136,522.74. The disclosure for this sale can be found here. Insiders sold 53,120 shares of company stock valued at $25,528,753 over the last three months. 0.90% of the stock is owned by corporate insiders.

Intuitive Surgical Stock Down 1.3 %

Intuitive Surgical stock opened at $484.76 on Wednesday. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $496.48. The firm has a market cap of $171.94 billion, a PE ratio of 87.50, a price-to-earnings-growth ratio of 5.39 and a beta of 1.39. The company’s 50 day moving average is $474.22 and its two-hundred day moving average is $430.19.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same period in the prior year, the firm earned $1.18 earnings per share. The business’s quarterly revenue was up 14.5% compared to the same quarter last year. On average, equities research analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ISRG has been the subject of several recent research reports. Stifel Nicolaus boosted their target price on shares of Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research report on Friday, July 19th. BTIG Research upped their price objective on Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a research note on Wednesday, August 28th. JPMorgan Chase & Co. boosted their price target on Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a report on Friday, July 19th. Piper Sandler raised their price objective on Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research note on Friday, July 19th. Finally, Evercore ISI increased their target price on shares of Intuitive Surgical from $410.00 to $475.00 and gave the stock an “in-line” rating in a report on Tuesday. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus price target of $449.70.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.